KR100845450B1 - 약학적 제형물로서의 세로토닌 아고니스트 (5에이치티2)및 안타고니스트 (5에이치티6) 의 새로운 조합 - Google Patents

약학적 제형물로서의 세로토닌 아고니스트 (5에이치티2)및 안타고니스트 (5에이치티6) 의 새로운 조합 Download PDF

Info

Publication number
KR100845450B1
KR100845450B1 KR1020037000321A KR20037000321A KR100845450B1 KR 100845450 B1 KR100845450 B1 KR 100845450B1 KR 1020037000321 A KR1020037000321 A KR 1020037000321A KR 20037000321 A KR20037000321 A KR 20037000321A KR 100845450 B1 KR100845450 B1 KR 100845450B1
Authority
KR
South Korea
Prior art keywords
receptor
delete delete
ethoxy
antagonist
type described
Prior art date
Application number
KR1020037000321A
Other languages
English (en)
Korean (ko)
Other versions
KR20030036599A (ko
Inventor
요산수크윈데르
닐손비에른엠
사카리아센셸에스
스바르텡렌얀
Original Assignee
바이오비트럼 에이비(피유비엘)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오비트럼 에이비(피유비엘) filed Critical 바이오비트럼 에이비(피유비엘)
Publication of KR20030036599A publication Critical patent/KR20030036599A/ko
Application granted granted Critical
Publication of KR100845450B1 publication Critical patent/KR100845450B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
KR1020037000321A 2000-07-21 2001-07-19 약학적 제형물로서의 세로토닌 아고니스트 (5에이치티2)및 안타고니스트 (5에이치티6) 의 새로운 조합 KR100845450B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0002754-0 2000-07-21
SE0002754A SE0002754D0 (sv) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination
PCT/SE2001/001651 WO2002008178A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation

Publications (2)

Publication Number Publication Date
KR20030036599A KR20030036599A (ko) 2003-05-09
KR100845450B1 true KR100845450B1 (ko) 2008-07-10

Family

ID=20280577

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037000321A KR100845450B1 (ko) 2000-07-21 2001-07-19 약학적 제형물로서의 세로토닌 아고니스트 (5에이치티2)및 안타고니스트 (5에이치티6) 의 새로운 조합

Country Status (19)

Country Link
EP (1) EP1301476A1 (sh)
JP (1) JP2004504376A (sh)
KR (1) KR100845450B1 (sh)
CN (1) CN1221254C (sh)
AU (2) AU8273401A (sh)
BR (1) BR0112661A (sh)
CA (1) CA2411192A1 (sh)
EA (1) EA006604B1 (sh)
HK (1) HK1057536A1 (sh)
HU (1) HUP0301346A3 (sh)
IL (1) IL154057A0 (sh)
MX (1) MXPA03000548A (sh)
NO (1) NO20030304L (sh)
NZ (1) NZ523216A (sh)
PL (1) PL360309A1 (sh)
SE (1) SE0002754D0 (sh)
WO (1) WO2002008178A1 (sh)
YU (1) YU2603A (sh)
ZA (1) ZA200210234B (sh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
HUP0303756A3 (en) * 2000-11-02 2009-08-28 Wyeth Corp 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands and process for their preparation and pharmaceutical compositions containing them
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
JP2005501019A (ja) * 2001-06-15 2005-01-13 エフ．ホフマン−ラ　ロシュ　アーゲー ５−ｈｔ６レセプター親和性を有する４−ピペラジニルインドール誘導体
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
PT1497266E (pt) 2002-03-27 2008-09-10 Glaxo Group Ltd Derivados de quinolina e sua utilização como ligandos 5-ht6
CL2004000826A1 (es) * 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
MXPA06000795A (es) 2003-07-22 2006-08-23 Arena Pharm Inc Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo.
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
US8158617B2 (en) 2006-05-16 2012-04-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
WO2007149728A2 (en) * 2006-06-20 2007-12-27 Alcon Research, Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
ES2358288T3 (es) * 2007-08-01 2011-05-09 Laboratorios Del Dr. Esteve S.A. Combinación de al menos dos ligandos de 5ht6.
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
BRPI1011502A2 (pt) 2009-06-15 2016-03-22 Takeda Pharmaceutical composto, pró-droga, medicamento, método para a profilaxia ou tratamento de um sintoma do trato urinário inferior, obesidade, e/ou prolapso de órgão em um mamífero, e, uso do composto.
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
EP4119141A1 (en) 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE
CN111269165A (zh) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 一种3-芳基磺酰基吲哚衍生物的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO2000012510A1 (en) * 1998-09-01 2000-03-09 Vernalis Research Limited Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO2000012510A1 (en) * 1998-09-01 2000-03-09 Vernalis Research Limited Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists

Also Published As

Publication number Publication date
ZA200210234B (en) 2004-03-18
IL154057A0 (en) 2003-07-31
AU8273401A (en) 2002-02-05
BR0112661A (pt) 2003-06-24
EA006604B1 (ru) 2006-02-24
CN1443162A (zh) 2003-09-17
AU2001282734B2 (en) 2006-10-12
NZ523216A (en) 2005-05-27
KR20030036599A (ko) 2003-05-09
HUP0301346A2 (hu) 2003-08-28
CA2411192A1 (en) 2002-01-31
HK1057536A1 (en) 2004-04-08
MXPA03000548A (es) 2004-04-05
SE0002754D0 (sv) 2000-07-21
HUP0301346A3 (en) 2005-05-30
EA200300183A1 (ru) 2003-08-28
JP2004504376A (ja) 2004-02-12
PL360309A1 (en) 2004-09-06
NO20030304L (no) 2003-03-12
NO20030304D0 (no) 2003-01-20
EP1301476A1 (en) 2003-04-16
CN1221254C (zh) 2005-10-05
WO2002008178A1 (en) 2002-01-31
YU2603A (sh) 2006-05-25

Similar Documents

Publication Publication Date Title
KR100845450B1 (ko) 약학적 제형물로서의 세로토닌 아고니스트 (5에이치티2)및 안타고니스트 (5에이치티6) 의 새로운 조합
AU2001282734A1 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
KR102133073B1 (ko) 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물
ES2328671T3 (es) Compuestos de piperazilpirazinas como antagonistas del receptor de serotonina 5-ht2.
JP5711813B2 (ja) βセクレターゼ（ＢＡＣＥ）の阻害剤として有用な５，６−ジヒドロ−２Ｈ−［１，４］オキサジン−３−イル−アミン誘導体
CN1335850A (zh) 化合物
JP2011006431A (ja) アデノシンＡ２ａレセプターアンタゴニストの使用
TW201004939A (en) Novel compounds
CN116096715A (zh) 用于精神障碍或精神增强的有益苯并噻吩组合物
TWI614244B (zh) 吲哚啉-２-酮衍生物
US6818639B2 (en) Pharmaceutical combination formulation and method of treatment with the combination
JP2010516733A (ja) 新規医薬組成物
JP2007500168A (ja) １−スルホニルインドール誘導体、それらの調製及び５−ｈｔ６リガンドとしてのそれらの使用
US7618650B2 (en) Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof
KR100397525B1 (ko) 뇌혈관 장해에 수반되는 정신증후치료제
WO2010016552A1 (ja) 過敏性腸症候群治療薬
JP2010506884A (ja) Ｎｋ−１受容体アンタゴニストおよびｓｓｒｉを含む、耳鳴、聴力障害または耳鳴と聴力障害の治療用組成物
KR100890633B1 (ko) 세로토닌 수용체에 대한 친화력을 갖는 화합물
WO2023081306A1 (en) Indolizine compounds for the treatment of mental disorders or mental enhancement
EP1707206A1 (de) Piperazinderivate zur inhibition von Beta-Sekretase, Cathepsin D, Plasmepsin ll und HIV-Protease und zur Behandlung von Malaria, Alzheimer und AIDS
Baudy Patent Update Central & Peripheral Nervous Systems: Agents for the treatment of neurodegenerative diseases: January-June 1996
Baudy Patent Update Central & Peripheral Nervous Systems: Agents for the treatment of neurodegenerative diseases: Part 6

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110630

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee